Omega-3 Fatty Acids

Omega-3 fatty acids, also written as n-3 fatty acids, are polyunsaturated fatty acids in which the first double bond lies three carbon atoms from the terminal methyl group; that structural detail is what the name describes ^[1]. The three of greatest biological importance are alpha-linolenic acid (ALA), an 18-carbon fat from land plants, and two longer marine forms, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ^[1]. Humans cannot synthesize ALA, so it must be obtained from food, and the body converts ALA to EPA and DHA only inefficiently, which is why oily fish and algal oils are emphasized as direct sources of the long-chain forms ^[1].

Dietary omega-3s occur in fatty fish such as salmon, mackerel, herring, and sardines, in fish oil and krill oil supplements, and in plant foods including flaxseed, chia seeds, and walnuts, while microalgae are the original source of the EPA and DHA that build up along the marine food chain ^[1]. Inside the body these fats are incorporated into cell membranes, where DHA is especially concentrated in the brain and retina, and they act as precursors for signaling molecules that influence inflammation, including eicosanoids and the resolution-phase mediators known as resolvins, protectins, and maresins ^[2]. Through these routes marine omega-3s can temper several steps of the inflammatory response, an effect studied in conditions such as rheumatoid arthritis ^[2].

Omega-3s have been investigated extensively for cardiovascular and other outcomes, with results that are genuinely mixed ^[2][3]. High intakes reliably lower blood triglyceride levels, which underlies the approval of concentrated prescription products for hypertriglyceridemia ^[2]. Whether supplements prevent heart attacks, strokes, or death is more contested; a large Cochrane review found that increasing EPA and DHA has little or no effect on overall mortality or cardiovascular events for most people ^[3]. In contrast, a major randomized trial of a high-dose purified EPA medicine, icosapent ethyl, in statin-treated patients with elevated triglycerides reported a significant reduction in cardiovascular events, and reviews continue to weigh how dose, the particular fatty acid, and the comparison oil might explain such differences ^[4][2]. Research on mood, cognition, and other conditions has generally produced small or inconsistent effects.

Omega-3s are sold in several forms. As foods and over-the-counter dietary supplements, fish oil, krill oil, and algal oil are widely available and generally regarded as safe within customary intakes ^[1]. As medicines, purified preparations such as omega-3-acid ethyl esters, which contain both EPA and DHA, and icosapent ethyl, which contains EPA only, are prescription products used to lower very high triglyceride levels ^[2][4]. Reported drawbacks are usually mild, such as a fishy aftertaste or digestive upset, though high doses have been associated with a somewhat increased risk of atrial fibrillation and, because of mild effects on bleeding, warrant care in people taking blood thinners ^[4].

Omega-3s are usually taken as an over-the-counter supplement, with prescription versions for high triglycerides. They are well tolerated; the most common complaints are a fishy aftertaste or burps, mild indigestion, and loose stools, all reduced by taking them with meals or using an enteric-coated product. At the high doses used for triglycerides they can slightly raise bleeding tendency and, in some trials, the risk of atrial fibrillation. They are not a treatment for existing heart disease on their own, and supplement quality varies, so a reputable product matters.

Omega-3 fatty acids inhibit platelet aggregation and carry a documented risk of bleeding when combined with anticoagulants like warfarin. The mechanism is pharmacodynamic; both warfarin and omega-3 fish oil promote bleeding through independent pathways that sum together ^{[7] [8]}. High-dose omega-3 supplementation (6 grams daily or higher) with warfarin has led to life-threatening bleeding, including subdural hematoma from minor trauma in elderly patients. A retrospective study of over 500 patients found that fish oil and krill oil at typical supplement doses did not significantly alter warfarin control in a monitored anticoagulation clinic, though case reports of severe bleeding with higher doses persist ^[9].

The interaction with aspirin is similarly pharmacodynamic and additive; aspirin plus omega-3 plus warfarin has appeared in case reports of uncontrollable bleeding ^[8]. What remains essentially unstudied is the interaction of omega-3 with direct oral anticoagulants (apixaban, rivaroxaban, dabigatran); clinical data in these combinations are sparse, and the risk is unknown. Omega-3 with antiplatelet agents like clopidogrel has not been formally characterized.

Checking a whole stack? Run it through interactions + stacks.

Interest in omega-3 fatty acids as more than ordinary dietary fat grew out of epidemiological work in the 1970s, when Danish investigators Hans Olaf Bang and Jorn Dyerberg studied the Inuit of Greenland and linked their fish- and marine-mammal-rich diet, and its high content of eicosapentaenoic acid, to low rates of heart disease. That observation launched decades of research into how EPA and its companion docosahexaenoic acid influence blood lipids, clotting, and inflammation.

Purified, high-dose preparations followed the ordinary fish-oil supplements onto the market; the prescription omega-3-acid ethyl ester product Lovaza received U.S. approval in 2004 for severe hypertriglyceridemia, and a highly purified EPA-only ester, icosapent ethyl, was approved in 2012 and later studied in large cardiovascular outcome trials. Alongside the marine forms, the plant-derived precursor alpha-linolenic acid was recognized as an essential fatty acid because humans cannot synthesize it. Today omega-3s span the full range from everyday food and supplements to regulated medicines, backed by one of the largest bodies of nutritional research in existence.

Few supplements have been studied as intensively as omega-3 fatty acids, and their strongest, most consistent evidence is for lowering elevated triglycerides, where high doses can reduce very high levels substantially and are used as prescription therapy. Large meta-analyses have also associated marine omega-3 intake with reductions in certain cardiovascular events such as fatal and total myocardial infarction, and the fats are widely valued for a favorable safety profile and roles that appear to reach into inflammation, brain, and eye health.

The honest picture is nuanced: outcome trials have disagreed, with the high-profile STRENGTH trial finding no cardiovascular benefit from a combined EPA and DHA formulation versus a corn-oil comparator, even as EPA-focused trials reported benefit, so formulation and dose seem to matter. High doses can cause a fishy aftertaste, mild gastrointestinal upset, and a small increase in atrial fibrillation risk. As a well-tolerated, food-derived nutrient with clear lipid effects, omega-3s remain a reasonable and popular choice while research continues to refine who benefits most.